“Evaluation of Predictive Markers of HTLV-I Associated Disease in Jamaica”, in The 12th International Conference on Human Retrovirology: HTLV and Related Viruses, Montego Bay, Jamaica, 2005.
, “Seroincidence of HTLV-I infection and characterization of seroconverters in Jamaican food handlers”, J Acquir Immune Defic Syndr, vol. 33, pp. 387-392, 2003.
, “Seroincidence of human T-lymphotropic virus type I infection and characterization of seroconverters in Jamaican food handlers.”, J Acquir Immune Defic Syndr, vol. 33, no. 3, pp. 387-92, 2003.
, “Predictors of Agreement Between Hair Analysis and Self-Report of Drug Use”, in 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ, 2015.
, “A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
, “A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus”, AIDS Res Hum Retroviruses, vol. 26, pp. 933-942, 2010.
, “Safety and Immunogenicity of MVA.HIVA by 3 Different Routes”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
, “A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.”, AIDS Res Hum Retroviruses, vol. 26, no. 8, pp. 933-42, 2010.
, “PedsQL™ Cognitive Functioning Scale in pediatric liver transplant recipients: feasibility, reliability, and validity.”, Qual Life Res, vol. 20, no. 6, pp. 913-21, 2011.
, “PedsQL™ Cognitive Functioning Scale in Pediatric Liver Transplant Recipients: Feasibility, Reliability, and Validity”, Qual Life Res, vol. 20, pp. 913-921, 2011.
, “In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.”, PLoS One, vol. 6, no. 5, p. e19252, 2011.
, “Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine”, PLoS ONE, vol. 5, p. e8617, 2010.
, “Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8617, 2010.
, “Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 Clade B'/C Candidate Vaccine”, PLOS One, vol. 5, p. e8816, 2010.
, “Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
, “Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8816, 2010.
, , “Optical Coherence Tomography Reflective Drusen Substructures Predict Progression to Geographic Atrophy in Age-related Macular Degeneration.”, Ophthalmology, vol. 123, no. 12, pp. 2554-2570, 2016.
, “Treatments for hypersensitive noncarious cervical lesions: a Practitioners Engaged in Applied Research and Learning (PEARL) Network randomized clinical effectiveness study.”, J Am Dent Assoc, vol. 144, no. 5, pp. 495-506, 2013.
, “Treatments for Hypersensitive Noncarious Cervical Lesions: A Practitioners Engaged in Applied Research and Learning (PEARL) Network Randomized Clinical Effectiveness Study”, J Am Dent Assoc, vol. 144, pp. 495-506, 2013.
, “A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.”, J Acquir Immune Defic Syndr Hum Retrovirol, vol. 12, no. 5, pp. 462-9, 1996.
, “Frontloading In The Real-World: Leveraging Smartphone Technology To Examine Rate Of Alcohol Consumption Effects On Subjective Responses In Heavy Drinkers”, in 45th Annual Speaker & Poster Abstracts of the Research Society on Alcoholism, Orlando, Florida, 2022.
, “Prevalence of persistent pain 3 to 5 years post primary root canal therapy and its impact on oral health-related quality of life: PEARL Network findings.”, J Endod, vol. 40, no. 12, pp. 1917-21, 2014.
, “Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.”, PLoS One, vol. 16, no. 11, p. e0259361, 2021.
, “Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416”, Oncology, vol. 14, pp. 13121315-16
1321-23, 2000.
,